Trastuzumab-induced cardiomyopathy.
Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. It improves survival and increases response to chemotherapy. The major side effect of trastuzumab is cardiotoxicity manifesting as a reduction in left ventricular systolic function, either asymptomatic or with signs and symptoms of heart failure. Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab. The objective of this review is to summarize facts about trastuzumab-induced cardiotoxicity and to highlight the areas of future investigations. We searched PubMed for trials involving trastuzumab used as an adjuvant therapy for breast cancer, including the metastatic breast cancer setting, and focused on cardiotoxicity.
University of South Florida, Tampa, Florida, USA.
Maya
M
Guglin
Raymond
R
Cutro
Joseph D
JD
Mishkin
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D032342:Muscle Cells / Q000187:drug effects; D020890:Neuregulin-1 / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects; D012307:Risk Factors; D013315:Stress, Psychological; D000068878:Trastuzumab; D016277:Ventricular Function, Left
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab